Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › clopidogrel

clopidogrel

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of clopidogrel

80 trials tracked of clopidogrel: 49 in phase 3 or 4 and 18 with published results. The most-cited published study has 1506 citations.

80Trials tracked
49Phase 3 & 4
0Recruiting
18With published results
Phase distribution
Phase 4 32 Phase 3 17 Phase 2 18 Phase 1 9 Other / NA 4
  1. Phase 4 Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study) Completed · 1,506 cited
  2. Phase 3 Edoxaban Treatment Versus Vitamin K Antagonist in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Completed · 669 cited
  3. Phase 4 Tailored Antiplatelet Therapy Following PCI Completed · 411 cited
  4. Phase 3 Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT) Completed · 284 cited
  5. Phase 4 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Completed · 82 cited
  6. Phase 3 A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention Completed · 77 cited
Show 44 more trials
  1. Phase 4 Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Completed · 57 cited
  2. Phase 4 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction Completed · 54 cited
  3. Phase 3 GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation Completed · 50 cited
  4. Phase 4 Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Completed · 26 cited
  5. Phase 4 Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Completed · 19 cited
  6. Phase 4 Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI Completed · 16 cited
  7. Phase 3 A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease Completed · 16 cited
  8. Phase 4 Clopidogrel and Aspirin Interaction Study-2 Completed · 11 cited
  9. Phase 4 Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Completed · 10 cited
  10. Phase 3 STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction Completed · 7 cited
  11. Phase 4 Impact of Chronic Kidney Disease on Clopidogrel Effects in Diabetes Mellitus Completed · 3 cited
  12. Phase 4 Clopidogrel Monotherapy in Patients With High Bleeding Risk Completed · 2 cited
  13. Phase 4 Pharmacogenomics of Antiplatelet Response - I Completed
  14. Phase 4 Effect of Prasugrel Versus Clopidogrel on Platelet Function After Bivalirudin Cessation Completed
  15. Phase 4 Clopidogrel Versus Ticagrelor in Type-2 Diabetes Completed
  16. Phase 4 Antiplatelet Therapy After Cardiac Arrest Completed
  17. Phase 4 P3AMI Antiplatelet Trial Completed
  18. Phase 4 Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction Completed
  19. Phase 4 Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Completed
  20. Phase 4 Inflammation and Thrombosis in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve Replacement (TAVR) Completed
  21. Phase 4 CES1 Carriers in the PAPI Study Completed
  22. Phase 4 CES1 Crossover Trial of Clopidogrel and Ticagrelor Completed
  23. Phase 4 Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis II Completed
  24. Phase 4 PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes Completed
  25. Phase 4 Investigation of the Athero-Protective Effects of Clopidogrel Completed
  26. Phase 4 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study) Completed
  27. Phase 4 A Pharmacodynamic Study With Ticagrelor in Hispanic Patients Completed
  28. Phase 4 Prasugrel/Clopidogrel Maintenance Dose Washout Study Completed
  29. Phase 4 A Phase IV Study of the Onset and Maintenance of the Antiplatelet Effect of Ticagrelor Compared With Clopidogrel in Chinese Patients With ACS Completed
  30. Phase 4 A Pharmacodynamic Study With Ticagrelor in African American Patients Completed
  31. Phase 4 The Influence of Smoking Status on Prasugrel and Clopidogrel Treated Subjects Taking Aspirin and Having Stable Coronary Artery Disease Completed
  32. Phase 4 Ad Hoc Percutaneous Coronary Intervention Study in Acute Coronary Syndrome Patients Completed
  33. Phase 3 Efficacy and Safety of Low-dose Ticagrelor Completed
  34. Phase 3 Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities Completed
  35. Phase 3 Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation Completed
  36. Phase 3 A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome Completed
  37. Phase 3 Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS Completed
  38. Phase 3 Study to Assess Safety and Efficacy of Ticagrelor (AZD6140) Versus Clopidogrel in Asian/Japanese Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) Completed
  39. Phase 3 Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry Completed
  40. Phase 3 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention Completed
  41. Phase 3 Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events Completed
  42. Phase 3 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Completed
  43. Phase 3 A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Completed
  44. Phase 2 Cangrelor to Clopidogrel or Prasugrel Transition Study Completed

Showing the 50 most-cited and recently-updated of 80 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients
Cardiology Meta-analysis
Ticagrelor reduces mortality and major adverse cardiovascular events compared to clopidogrel in STEMI patients Ticagrelor Shows Lower Mortality Risk Than Clopidogrel for Heart Patients
This meta-analysis of 31,729 adult STEMI patients post-PCI found that ticagrelor significantly reduced all-cause mortality (OR = 0.64) and m…
A large analysis of over 31,000 patients suggests ticagrelor may lower mortality and heart attack risks compared to clopidogrel after a hear…
NEJM Jul 26, 2026
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients
Cardiology RCT
Lower aspirin doses combined with clopidogrel may reduce ischemic events in high risk patients Lower Aspirin Doses May Be Safer for Patients After Minor Strokes
Researchers analyzed data from a trial involving patients with transient ischemic attack and minor stroke receiving dual antiplatelet therap…
Doctors found that taking a lower dose of aspirin with clopidogrel may reduce the risk of serious heart and brain events.
Jul 21, 2026
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk
Cardiology RCT
Extended DAPT with clopidogrel and aspirin reduces cardiovascular death, myocardial infarction, and stroke risk Extended dual antiplatelet therapy lowers risks for heart disease patients
This randomized trial of 8250 patients with multivessel coronary artery disease found that extending dual antiplatelet therapy (DAPT) for an…
Patients with coronary artery disease may have lower risks of stroke and heart attack when taking two blood thinners for an extra year.
Jul 16, 2026
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes
Diabetes & Endocrinology RCT
General medical management improves medication adherence and lifestyle outcomes in older adults with type 2 diabetes New management model improves medication use and health for seniors
This randomized controlled trial of 200 older adults with type 2 diabetes and atherosclerotic cardiovascular disease found that a general me…
A new personalized care plan helps older adults with diabetes and heart disease stay on their medications and improve their daily habits.
Jun 26, 2026
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response
Neurology RCT
Tirofiban Adjunct Therapy Improves Outcomes in Patients with Inadequate Tenecteplase Response Trial shows tirofiban improves outcomes for some stroke patients
Intravenous tirofiban significantly improves 90-day functional outcomes for acute ischemic stroke patients failing initial tenecteplase ther…
A new clinical trial suggests that adding tirofiban can improve recovery rates for certain types of stroke patients who do not respond well …
JAMA Jun 13, 2026
Pantoprazole exposure linked to insulin autoimmune syndrome in case report
Diabetes & Endocrinology Sys. Review
Pantoprazole exposure linked to insulin autoimmune syndrome in case report Stopping a stomach acid drug helped a patient with low blood sugar recover
This case report describes a patient with insulin autoimmune syndrome (IAS) temporally associated with pantoprazole exposure. Discontinuatio…
A patient with insulin autoimmune syndrome found relief when doctors stopped a common stomach acid medication, suggesting a possible link be…
Frontiers Jun 3, 2026
FDA approves ticagrelor for multiple indications in cardiology and neurology
Cardiology FDA Approval
FDA approves ticagrelor for multiple indications in cardiology and neurology Brilinta Now Approved for Stroke Prevention in Three Key Groups
The FDA approved ticagrelor (Brilinta) for patients with ACS, CAD at high risk, and acute ischemic stroke or high-risk TIA. In ACS, it was s…
A widely used heart medication now has FDA approval to prevent first strokes in people with diabetes and to protect against repeat strokes a…
FDA May 14, 2026
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients
Cardiology RCT
Tailored antiplatelet strategy showed no benefit over standard dual therapy in high-risk PCI patients New heart drug plan failed to beat standard care for high-risk patients
This randomized clinical trial compared a tailored antiplatelet strategy involving early low-dose ticagrelor followed by late de-escalation …
Doctors tested a custom heart drug plan but found standard treatment still works best for high-risk patients
May 5, 2026
VerifyNow-guided antiplatelet modification linked to lower stroke recurrence in atherothrombotic or lacunar infarction
Neurology RCT
VerifyNow-guided antiplatelet modification linked to lower stroke recurrence in atherothrombotic or lacunar infarction Testing Blood Saves Stroke Patients From Recurrence
A retrospective observational study of 243 patients with atherothrombotic or lacunar infarction found that VerifyNow-guided antiplatelet the…
Doctors who adjusted blood thinner choices based on a simple blood test saw far fewer repeat strokes in patients with prior clots.
medRxiv Apr 16, 2026
Infliximab in IVIG-resistant Kawasaki disease with cholestatic hepatitis: case report
Pediatrics RCT
Infliximab in IVIG-resistant Kawasaki disease with cholestatic hepatitis: case report Can a new drug stop heart damage in Kawasaki disease when standard treatments fail?
A case report describes a 2-year-old Han Chinese male with IVIG-resistant Kawasaki disease and cholestatic hepatitis treated with infliximab…
In a two-year-old boy with Kawasaki disease, the drug infliximab quickly stopped his fever and liver trouble, yet his heart artery damage ke…
Frontiers Apr 16, 2026
Cerebral infarction common in tuberculous meningitis and linked to disease severity and arterial occlusion
Neurology RCT
Cerebral infarction common in tuberculous meningitis and linked to disease severity and arterial occlusion Could blood thinners or specific treatments make brain strokes worse in severe meningitis?
This secondary analysis of the ACT-TBM randomized trial examined 226 patients with tuberculous meningitis at two tertiary centers in India.
Patients with tuberculous meningitis and blocked arteries were much more likely to develop strokes, especially if they received modified tub…
Apr 15, 2026
Ten-year HOST-EXAM trial data show clopidogrel reduces major adverse events versus aspirin in chronic PCI maintenance
Cardiology RCT
Ten-year HOST-EXAM trial data show clopidogrel reduces major adverse events versus aspirin in chronic PCI maintenance Long-term clopidogrel may lower risks compared to aspirin after heart stents
This 10-year extended follow-up of the HOST-EXAM randomized controlled trial evaluated clopidogrel versus aspirin in 5,438 patients during t…
After heart stents, long-term clopidogrel alone lowered risks of major heart events and death compared to aspirin alone in a 10-year study.
Apr 14, 2026

All clopidogrel Articles